Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5190797 | 1.00 | MEN1 (0.40) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL5189224 | 1.00 | MEN1 (0.40) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL176327 | 0.98 | MEN1 (0.37) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL28718183 | 0.91 | USP2 (0.44) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL303130 | 0.91 | USP2 (0.44) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL28823669 | 0.91 | USP2 (0.44) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL29064941 | 0.91 | USP2 (0.44) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL4204839 | 0.91 | USP2 (0.44) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL4204713 | 0.91 | USP2 (0.44) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL28869452 | 0.91 | USP2 (0.44) | MEN1KMT2AHTTMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200315967-A1 | LIPID NANOPARTICLES | MODERNATX, INC. (US) | 2020-10-08 | — | — | US | claimed |
| WO-2017223135-A1 | LIPID NANOPARTICLES | MODERNATX, INC. (US) | 2017-12-28 | — | — | WO | claimed |
| EP-3247328-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PhaseRx, Inc. (US) | 2017-11-29 | — | — | EP | claimed |
| WO-2016118697-A9 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-09-29 | — | — | WO | claimed |
| WO-2016118697-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-07-28 | — | — | WO | claimed |
| US-20240243975-A1 | USE OF INVERTED TERMINAL REPEATS (ITRS) FROM ADENO-ASSOCIATED VIRUS SEROTYPES 8 AND RH.39 IN GENE THERAPY VECTORS | UNIVERSITY OF MASSACHUSETTS (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240226324-A1 | NON-VIRAL DNA VECTORS EXPRESSING THERAPEUTIC ANTIBODIES AND USES THEREOF | GENERATION BIO CO. | 2024-07-11 | — | — | US | disclosed |
| WO-2024119039-A2 | STEALTH LIPID NANOPARTICLES AND USES THEREOF | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240181085-A1 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING PFIC THERAPEUTICS | GENERATION BIO CO. | 2024-06-06 | — | — | US | disclosed |
| WO-2024119017-A1 | SYNTHETIC SINGLE STRANDED NUCLEIC ACID COMPOSITIONS AND METHODS THEREOF | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024119103-A1 | LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS AND LIPID-ANCHORED POLYMERS | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024119116-A1 | SYNTHETIC SINGLE-STRANDED DNA MOLECULES AND METHODS OF PRODUCING AND USING THE SAME | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-3423110-A1 | CLOSED-ENDED LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER | University of Massachusetts (US) | 2019-01-09 | — | — | EP | disclosed |
| WO-2018160887-A1 | PDL1-SPECIFIC AND BETA-CATENIN-SPECIFIC ASYMMETRIC INTERFERING RNA COMPOSITIONS, USES OR PREPARATION THEREOF | BOSTON BIOMEDICAL, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180221402-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | ROIVANT SCIENCES LTD. (GB) | 2018-08-09 | — | — | US | disclosed |
| WO-2017223135-A1 | LIPID NANOPARTICLES | MODERNATX, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-3247328-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PhaseRx, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118697-A9 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016118697-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2009108235-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES TO NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226324-A1 | NON-VIRAL DNA VECTORS EXPRESSING THERAPEUTIC ANTIBODIES AND USES THEREOF | DNASE1L3, HAVCR2, CD2BP2 | MEN1 1741/4885KMT2A 1660/4885HTT 2610/4885 |
| US-20200315967-A1 | LIPID NANOPARTICLES | EXOSC9, ABCB4, LIPA | MEN1 3717/4885KMT2A 2250/4885HTT 306/4885 |
| US-20240181085-A1 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING PFIC THERAPEUTICS | ABCB4, ABCC8, ABCB1 | MEN1 3876/4885KMT2A 3172/4885HTT 2847/4885 |
| US-20180221402-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | CD63, LIPA, NPC1L1 | MEN1 2379/4885KMT2A 4574/4885HTT 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.